研究課題
In this study, we found that CYGB deficiency promotes liver fibrosis and cancer development in a non-alcoholic steatohepatitis model in mice via activation of oxidative stress pathway (Am J Pathol 2015;185:1045-60). Therefore, the absence of CYGB likely promotes both fibrotic and carcinogenic process in chronic liver disease. CYGB which presences on HSCs and suppresses their activation should be considered primary target for the development of new antifibrotic therapies.
2: おおむね順調に進展している
Liver fibrosis and cirrhosis accounts for up to 45% of death in developed countries, while we still lack effective antifibrotic therapies.We previously showed that Cygb-deficient mice exhibit susceptibility to cancer development in the liver and lung with diethylnitrosamine administration.Furthermore, in this study, we found that CYGB deficiency promotes liver fibrosis and cancer development in a non-alcoholic steatohepatitis model in mice via activation of oxidative stress pathway.Therefore, the absence of CYGB likely promotes both fibrotic and carcinogenic process in chronic liver disease.The important concern should be the protective role of CYGB in liver fibrosis development. CYGB which presences on HSCs and suppresses their activation should be considered primary target for the development of new antifibrotic therapies.
Explore the mechanism action of CYGB in preventing liver fibrosis and cancer development. Recombinant human CYGB protein will be produced and examined its antifibrotic activity. Animal model of alcoholic induced liver diseases will be established.
謝金の支払いが不要となったため。
物品購入に使用する予定である。
すべて 2015 2014 その他
すべて 雑誌論文 (4件) 学会発表 (1件) 備考 (1件)
Am J Pathol.
巻: 185 ページ: 1045-1060
Lab Invest.
巻: 00 ページ: 1-10
10.1038
巻: 94 ページ: 192-207
J Gastroenterol Hepatol.
巻: 29 ページ: 201-207
10.1111
http://www.med.osaka-cu.ac.jp/liver/index.html